Clinical course, chest computed tomography severity score and outcome of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases.
COVID-19
Computed tomography
Hospitalization
Mortality
Rheumatic diseases
Journal
The Egyptian rheumatologist
ISSN: 2090-2433
Titre abrégé: Egypt Rheumatol
Pays: Netherlands
ID NLM: 9885165
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
31
12
2021
accepted:
31
12
2021
medline:
1
6
2022
pubmed:
1
6
2022
entrez:
31
7
2023
Statut:
ppublish
Résumé
To assess the clinical manifestations, imaging findings and outcomes of corona virus disease 2019 (COVID-19) in patients with rheumatic diseases. In a three-center study, patients with rheumatic diseases who developed COVID-19 were included. Patients were classified into two groups, i) inflammatory arthritis including rheumatoid arthritis (RA), spondyloarthritis (SpA) and undifferentiated arthritis, ii) connective tissue diseases (CTDs) including systemic lupus erythematosus (SLE), vasculitis and others. COVID-19 outcomes were assessed based on chest computed tomography severity score (CT-ss), the level of care, the number of patients who died and flare of underlying rheumatic disease. One hundred ninety-six patients with a mean age of 47.9 ± 15.1 years, 73.5% female, were included. Underlying rheumatic diseases were RA (57.7%), SLE and other CTDs (17.9%), SpA (11.2%), vasculitis (11.2%) and undifferentiated arthritis (2%). Myalgia, malaise and fever were the most common clinical manifestations of COVID-19. Pneumonia on computerized tomography (CT), hospitalization, admission in intensive care unit and need to mechanical ventilation were observed in 75.5, 37.2%, 10.7% and 6.6% of patients, respectively. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, diabetes and underlying pulmonary disease were predictors of moderate to severe pneumonia and hospitalization. Fifteen (7.6%) patients died. Flare of underlying rheumatic disease occurred in 16.3% of patients. Flare of disease in patients with CTDs was significantly more than other rheumatic diseases. In rheumatic patients, treatment with NSAIDs or prednisolone, diabetes and pulmonary disease are risk factors of moderate to high CT-ss and hospitalization during COVID-19.
Identifiants
pubmed: 37521094
doi: 10.1016/j.ejr.2021.12.010
pii: S1110-1164(21)00121-6
pmc: PMC8730740
doi:
Types de publication
Journal Article
Langues
eng
Pagination
245-250Informations de copyright
© 2021 Egyptian Society for Joint Diseases and Arthritis.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Lancet Rheumatol. 2021 Jul;3(7):e498-e506
pubmed: 33997800
RMD Open. 2020 Sep;6(2):
pubmed: 32878994
Rheumatol Int. 2020 Oct;40(10):1599-1611
pubmed: 32710198
Arthritis Rheumatol. 2020 Dec;72(12):1981-1989
pubmed: 32725762
Rheumatol Int. 2020 Oct;40(10):1593-1598
pubmed: 32794113
Clin Rheumatol. 2020 Nov;39(11):3195-3204
pubmed: 32852623
Radiology. 2005 Sep;236(3):1067-75
pubmed: 16055695
Gut. 2020 Jul;69(7):1213-1217
pubmed: 32354990
Rheumatol Int. 2021 Sep;41(9):1607-1616
pubmed: 34244818
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Lancet Rheumatol. 2022 Feb;4(2):e85-e87
pubmed: 34901886
Curr Med Res Opin. 2004 Jan;20(1):39-40
pubmed: 14741070
Eur J Rheumatol. 2020 Aug;7(Suppl 2):S134-S136
pubmed: 32352363
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Rheumatol Int. 2021 Feb;41(2):345-353
pubmed: 33130920
Arthritis Res Ther. 2011 Aug 31;13(4):R139
pubmed: 21884589
Scand J Infect Dis. 2009;41(4):268-74
pubmed: 19172435
Lancet Rheumatol. 2020 May;2(5):e250-e253
pubmed: 32309814
RMD Open. 2021 Sep;7(3):
pubmed: 34493645
Ann Rheum Dis. 2021 Mar;80(3):384-391
pubmed: 33051220
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
Ann Rheum Dis. 2020 Nov;79(11):1393-1399
pubmed: 32769150